Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.67 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.67 |
| ▸ | HTR2A | P28223 | 4/20 | 0.59 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.49 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.49 |
| ▸ | HTR1D | P28221 | 1/20 | 0.49 |
| ▸ | HTR1B | P28222 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | HTR1E | P28566 | 1/20 | 0.49 |
| ▸ | HTR7 | P34969 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7335081 | 0.88 | CSNK2A1 (0.60) | CSNK2A1GPR84HTR2ATRPM8SLC6A4 | |
| SCHEMBL6198753 | 0.87 | GPR84 (0.67) | CSNK2A1GPR84HTR2ATRPM8SLC6A4 | |
| SCHEMBL28107185 | 0.83 | GPR84 (0.67) | GPR84HTR2ATRPM8SLC6A4IDO1 | |
| SCHEMBL18383117 | 0.80 | GPR84 (1.00) | GPR84HTR2ATRPM8SLC6A4IDO1 | |
| SCHEMBL2005588 | 0.80 | CSNK2A1 (1.00) | CSNK2A1GPR84HTR2ATRPM8SLC6A4 | |
| SCHEMBL2004780 | 0.80 | CSNK2A1 (0.67) | CSNK2A1HTR2ASLC6A4IDO1HTR1A | |
| SCHEMBL14970013 | 0.80 | CSNK2A1 (0.67) | CSNK2A1HTR2ASLC6A4HTR1AADRA2A | |
| SCHEMBL2724522 | 0.80 | MPO (0.68) | CSNK2A1GPR84HTR2ATRPM8SLC6A4 | |
| SCHEMBL274224 | 0.80 | CSNK2A1 (0.67) | CSNK2A1GPR84HTR2ATRPM8SLC6A4 | |
| SCHEMBL949791 | 0.79 | GPR84 (0.76) | GPR84HTR2ATRPM8SLC6A4IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3307724-B1 | (Z)-2-(1H-INDOL-3-YL)-3-(ISOQUINOLIN-5-YL)ACRYLONITRILE DERIVATIVES AND RELATED COMPOUNDS WITH LYSOSOME INHIBITORY AND ANTI-MITOTIC ACTIVITY FOR TREATING HYPERPROLIFERATIVE DISEASES | NAT UNIV SINGAPORE (SG) | 2020-06-10 | — | — | EP | disclosed |
| EP-3307724-B1 | (Z)-2-(1H-INDOL-3-YL)-3-(ISOQUINOLIN-5-YL)ACRYLONITRILE DERIVATIVES AND RELATED COMPOUNDS WITH LYSOSOME INHIBITORY AND ANTI-MITOTIC ACTIVITY FOR TREATING HYPERPROLIFERATIVE DISEASES | NAT UNIV SINGAPORE (SG) | 2020-06-10 | — | — | EP | disclosed |
| US-10308631-B2 | Selective anti-cancer compounds | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2019-06-04 | — | — | US | disclosed |
| US-10308631-B2 | Selective anti-cancer compounds | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2019-06-04 | — | — | US | disclosed |
| US-20180179178-A1 | SELECTIVE ANTI-CANCER COMPOUNDS | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2018-06-28 | — | — | US | disclosed |
| US-20180179178-A1 | SELECTIVE ANTI-CANCER COMPOUNDS | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2018-06-28 | — | — | US | disclosed |
| US-20180179178-A1 | SELECTIVE ANTI-CANCER COMPOUNDS | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2018-06-28 | — | — | US | disclosed |
| EP-2445497-B1 | Use of derivatives of indoles for the treatment of cancer | CENTRE NAT DE LA RECH SCIENT (C N R S ) (FR) | 2017-08-02 | — | — | EP | disclosed |
| EP-2445497-B1 | Use of derivatives of indoles for the treatment of cancer | CENTRE NAT DE LA RECH SCIENT (C N R S ) (FR) | 2017-08-02 | — | — | EP | disclosed |
| WO-2016200339-A1 | SELECTIVE ANTI-CANCER COMPOUNDS | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2016-12-15 | — | — | WO | disclosed |
| US-20010041722-A1 | Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor | ALINEA PHARMACEUTICALS, INC. | 2001-11-15 | — | — | US | disclosed |
| EP-1135124-A2 | ANTIHYPERTRIGLYCERIDEMIC, ANTIHYPERGLYCEMIC, ANTI-ANGIOGENIC AND WOUND HEALING SUBSTITUDED INDOLEALKANOIC ACIDS | The Institutes for Pharmaceutical Discovery, Inc. (US) | 2001-09-26 | — | — | EP | disclosed |
| WO-2001064205-A2 | COMPOSITIONS CONTAINING A SUBSTITUTED INDOLEALKANOIC ACID AND AN ANGIOTENSIN CONVERTING ENZYME INHIBITOR | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2001-09-07 | — | — | WO | disclosed |
| US-20010016661-A1 | Substituted indolealkanoic acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY | 2001-08-23 | — | — | US | disclosed |
| WO-2001051489-A2 | METHODS FOR LOWERING URIC ACID LEVELS | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2001-07-19 | — | — | WO | disclosed |
| CN-1296485-A | Substituted indolealkanoic acids | INST FOR PHARM DISCOVERY INC (US) | 2001-05-23 | — | — | CN | disclosed |
| US-6214991-B1 | 3-(4,5,7-TRIFLUOROBENZOTHIAZOL-2-YL)METHYL-INDOLE-N-ACETIC ACID, ETHYL ESTER FOR EXAMPLE; TREATING COMPLICATIONS OF DIABETES MELLITUS, SUCH AS CATARACTS, RETINOPATHY, NEPHROPATHY, AND NEUROPATHY | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, INC. | 2001-04-10 | — | — | US | disclosed |
| EP-1066283-A2 | SUBSTITUTED INDOLEALKANOIC ACIDS | The Institutes for Pharmaceutical Discovery, Inc. (US) | 2001-01-10 | — | — | EP | disclosed |
| WO-2000032180-A2 | ANTIHYPERTRIGLYCERIDEMIC, ANTIHYPERGLYCEMIC, ANTI-ANGIOGENIC AND WOUND HEALING SUBSTITUTED INDOLEALKANOIC ACIDS | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, INC. (US) | 2000-06-08 | — | — | WO | disclosed |
| WO-1999050268-A2 | SUBSTITUTED INDOLEALKANOIC ACIDS | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, INC. (US) | 1999-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010016661-A1 | Substituted indolealkanoic acids | GPR119, AANAT, AADAT | CSNK2A1 3030/4885GPR84 722/4885HTR2A 101/4885 |
| US-10308631-B2 | Selective anti-cancer compounds | CCNA1, CCNY, CCNT1 | CSNK2A1 1142/4885GPR84 3913/4885HTR2A 4698/4885 |
| US-20180179178-A1 | SELECTIVE ANTI-CANCER COMPOUNDS | CCNA1, CCNY, CCNT1 | CSNK2A1 1142/4885GPR84 3913/4885HTR2A 4698/4885 |
| US-20010041722-A1 | Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor | AGT, LIPG, ACE | CSNK2A1 1852/4885GPR84 1281/4885HTR2A 774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.